Skip Navigation LinksHome > June 2010 - Volume 29 - Issue 6 > LONG-TERM EFFICACY AND SAFETY OF FOSAMPRENAVIR IN HUMAN IMMU...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e3181d285ac
Brief Reports

LONG-TERM EFFICACY AND SAFETY OF FOSAMPRENAVIR IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PEDIATRIC PATIENTS

Palladino, Claudia PhD*; Briz, Verónica PhD*; Policarpo, Sergio Negre MD†; Silveira, Laura Fernandez MD‡; de José, M Isabel MD§; González-Tomé, M Isabel MD¶; Moreno, David MD∥; León Leal, Juan A. MD**; Mellado, M José MD††; de Ory, Santiago J. BSc*; Ramos, José T. MD‡‡; Muñoz-Fernández, M Ángeles PhD, MD*

Supplemental Author Material
Collapse Box

Abstract

Fosamprenavir (FPV) efficacy in human immunodeficiency virus (HIV)-infected pediatric patients is still being evaluated in ongoing clinical trials. The long-term efficacy and safety of FPV boosted with ritonavir (FPV/r) was evaluated in 20 antiretroviral-naive and antiretroviral-experienced HIV-vertically infected pediatric patients. Analyses of CD4+ T-cells, HIV-ribonucleic acid (RNA), and clinical status were performed during a median of 180 weeks. Initially, median HIV-RNA was 4.6 log10 in naive and 4.4 log10 in pretreated patients. Median CD4+ T-cell was 17% and 31%, respectively. After FPV/r treatment, 18 of 20 patients achieved undetectable HIV-RNA and 4 of 20 experienced adverse events. To date, FPV/r treatment has shown sustained antiviral response and immunologic improvement in our 20 patients.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.